Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Tóm tắt
Từ khóa
Tài liệu tham khảo
http://eco.iarc.fr/EUCAN/CancerOne.aspx?Cancer=46&Gender=2#block-table-f (30 July 2015, date last accessed).
McTiernan, 2003, Behavioral risk factors in breast cancer: can risk be modified?, Oncologist, 8, 326, 10.1634/theoncologist.8-4-326
Autier, 2010, Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database, BMJ, 341, c3620, 10.1136/bmj.c3620
Allemani, 2015, Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2), Lancet, 385, 977, 10.1016/S0140-6736(14)62038-9
Giordano, 2012, Mammographic screening programmes in Europe: organization, coverage and participation, J Med Screen, 19, 72, 10.1258/jms.2012.012085
Perry, 2006
Association of European Cancer Leagues. European Union Council Recommendation on Cancer Screening. http://www.europeancancerleagues.org/cancer-in-europe/resources-on-cancer-in-europe/82-eu-council-recommendation-on-cancer-screening.html (30 July 2015, date last accessed).
Gøtzsche, 2011, Screening for breast cancer with mammography, Cochrane Database Syst Rev, 1
Lauby-Secretan, 2015, Breast-cancer screening—viewpoint of the IARC Working Group, N Engl J Med, 372, 2353, 10.1056/NEJMsr1504363
Independent UK Panel on Breast Cancer Screening, 2012, The benefits and harms of breast cancer screening: an independent review, Lancet, 380, 1778, 10.1016/S0140-6736(12)61611-0
Warner, 2008, Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer, Ann Intern Med, 148, 671, 10.7326/0003-4819-148-9-200805060-00007
Sardanelli, 2010, Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group, Eur J Cancer, 46, 1296, 10.1016/j.ejca.2010.02.015
Kuehn, 2013, Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study, Lancet Oncol, 14, 609, 10.1016/S1470-2045(13)70166-9
Boughey, 2013, Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial, JAMA, 310, 1455, 10.1001/jama.2013.278932
Lakhani, 2012
Hammond, 2011, American Society of Clinical Oncology-College of American Pathologists guidelines for breast predictive factor testing: an update, Appl Immunohistochem Mol Morphol, 19, 499, 10.1097/PAI.0b013e31822a8eac
Wolff, 2013, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, J Clin Oncol, 31, 3997, 10.1200/JCO.2013.50.9984
Dowsett, 2011, Assessment of Ki67 in breast cancer: recommendations from the International Ki-67 Breast Cancer Working Group, J Natl Cancer Inst, 103, 1656, 10.1093/jnci/djr393
Guiu, 2012, Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement, Ann Oncol, 23, 2997, 10.1093/annonc/mds586
Mann, 2005, Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer, J Clin Oncol, 23, 5148, 10.1200/JCO.2005.02.076
Chen, 2012, Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis, Breast Cancer Res Treat, 134, 957, 10.1007/s10549-012-1990-z
Coates, 2015, Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015, Ann Oncol, 26, 1533, 10.1093/annonc/mdv221
Edge, 2010
Harris, 2007, American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer, J Clin Oncol, 25, 5287, 10.1200/JCO.2007.14.2364
Koolen, 2012, 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques, Breast Cancer Res Treat, 131, 117, 10.1007/s10549-011-1767-9
Robertson, 2011, FDG-PET/CT in the staging of local/regional metastases in breast cancer, Breast, 20, 491, 10.1016/j.breast.2011.07.002
Blamey, 2007, Reading the prognosis of the individual with breast cancer, Eur J Cancer, 43, 1545, 10.1016/j.ejca.2007.01.003
Ravdin, 2001, Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer, J Clin Oncol, 19, 980, 10.1200/JCO.2001.19.4.980
Wishart, 2011, A population-based validation of the prognostic model PREDICT for early breast cancer, Eur J Surg Oncol, 37, 411, 10.1016/j.ejso.2011.02.001
Harbeck, 2014, Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow, Cancer Treat Rev, 40, 434, 10.1016/j.ctrv.2013.09.014
Wazir, 2014, Emerging gene-based prognostic tools in early breast cancer: first steps to personalised medicine, World J Clin Oncol, 5, 795, 10.5306/wjco.v5.i5.795
Drukker, 2013, A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study, Int J Cancer, 133, 929, 10.1002/ijc.28082
Bossuyt, 2015, Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration, Ann Oncol, 26, 1280, 10.1093/annonc/mdv161
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM305501.pdf (30 July 2015, date last accessed).
Del Turco, 2010, Quality indicators in breast cancer care, Eur J Cancer, 46, 2344, 10.1016/j.ejca.2010.06.119
EUSOMA, 2000, The requirements of a specialist breast unit, Eur J Cancer, 36, 2288, 10.1016/S0959-8049(00)00180-5
Wilson, 2013, The requirements of a specialist Breast Centre, Eur J Cancer, 49, 3579, 10.1016/j.ejca.2013.07.017
Pruthi, 2010, Identification and management of women with BRCA mutations or hereditary predisposition for breast and ovarian cancer, Mayo Clin Proc, 85, 1111, 10.4065/mcp.2010.0414
Senkus, 2014, Young breast cancer patients' attitudes towards the risk of loss of fertility related to adjuvant therapies. EORTC study 10002 BIG 3–98, Psychooncology, 23, 173, 10.1002/pon.3384
Lee, 2006, American Society of Clinical Oncology recommendations on fertility preservation in cancer patients, J Clin Oncol, 24, 2917, 10.1200/JCO.2006.06.5888
Partridge, 2014, First international consensus guidelines for breast cancer in young women (BCY1), Breast, 23, 209, 10.1016/j.breast.2014.03.011
Cardoso, 2012, The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer, Eur J Cancer, 48, 3355, 10.1016/j.ejca.2012.10.004
Association of Breast Surgery at Baso 2009, 2009, Surgical guidelines for the management of breast cancer, Eur J Surg Oncol, 35, 1, 10.1016/j.ejso.2009.01.008
Schnitt, 2015, The Society of Surgical Oncology-American Society for Radiation Oncology Consensus Guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer: perspectives for pathologists, Arch Pathol Lab Med, 139, 575, 10.5858/arpa.2014-0384-ED
Houssami, 2010, Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy, Eur J Cancer, 46, 3219, 10.1016/j.ejca.2010.07.043
Moran, 2014, Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer, J Clin Oncol, 32, 1507, 10.1200/JCO.2013.53.3935
Poortmans, 2012, Quality indicators for breast cancer: revisiting historical evidence in the context of technology changes, Semin Radiat Oncol, 22, 29, 10.1016/j.semradonc.2011.09.007
Chatterjee, 2009, Effect of postoperative radiotherapy on autologous deep inferior epigastric perforator flap volume after immediate breast reconstruction, Br J Surg, 96, 1135, 10.1002/bjs.6693
Senkus-Konefka, 2004, Radiotherapy for breast cancer in patients undergoing breast reconstruction or augmentation, Cancer Treat Rev, 30, 671, 10.1016/j.ctrv.2004.06.008
Donker, 2014, Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial, Lancet Oncol, 15, 1303, 10.1016/S1470-2045(14)70460-7
Gebruers, 2015, Incidence and time path of lymphedema in sentinel node negative breast cancer patients: a systematic review, Arch Phys Med Rehabil, 96, 1131, 10.1016/j.apmr.2015.01.014
Lyman, 2014, Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update, J Clin Oncol, 32, 1365, 10.1200/JCO.2013.54.1177
Krag, 2010, Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial, Lancet Oncol, 11, 927, 10.1016/S1470-2045(10)70207-2
Giuliano, 2011, Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer, JAMA, 306, 385, 10.1001/jama.2011.1034
NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Version 3.2014, http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (30 July 2015, date last accessed).
Kaufmann, 2010, Locoregional treatment of primary breast cancer: consensus recommendations from an International expert panel, Cancer, 116, 1184, 10.1002/cncr.24874
Weaver, 2010, Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale, Mod Pathol, 23, S26, 10.1038/modpathol.2010.36
Galimberti, 2013, Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial, Lancet Oncol, 14, 297, 10.1016/S1470-2045(13)70035-4
Giuliano, 2011, Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial, JAMA, 305, 569, 10.1001/jama.2011.90
Leidenius, 2006, Tumour-positive sentinel node findings in patients with ductal carcinoma in situ, J Surg Oncol, 94, 380, 10.1002/jso.20581
Moore, 2007, Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit, Ann Surg Oncol, 14, 2911, 10.1245/s10434-007-9414-8
Meijnen, 2007, Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy, Br J Surg, 94, 952, 10.1002/bjs.5735
Yen, 2005, Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ, J Am Coll Surg, 200, 516, 10.1016/j.jamcollsurg.2004.11.012
Risch, 2006, Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada, J Natl Cancer Inst, 98, 1694, 10.1093/jnci/djj465
Antoniou, 2003, Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies, Am J Hum Genet, 72, 1117, 10.1086/375033
Liebens, 2007, Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006, Eur J Cancer, 43, 238, 10.1016/j.ejca.2006.07.019
Hwang, 2013, Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status, Cancer, 119, 1402, 10.1002/cncr.27795
Darby, 2011, Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials, Lancet, 378, 1707, 10.1016/S0140-6736(11)61629-2
Werkhoven, 2011, Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881–10882 boost versus no boost trial, Radiother Oncol, 100, 101, 10.1016/j.radonc.2011.07.004
Bartelink, 2015, Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial, Lancet Oncol, 16, 47, 10.1016/S1470-2045(14)71156-8
Veronesi, 2013, Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial, Lancet Oncol, 14, 1269, 10.1016/S1470-2045(13)70497-2
Vaidya, 2014, Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial, Lancet, 383, 603, 10.1016/S0140-6736(13)61950-9
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 2014, Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials, Lancet, 383, 2127, 10.1016/S0140-6736(14)60488-8
Kyndi, 2009, High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c, Radiother Oncol, 90, 74, 10.1016/j.radonc.2008.04.014
Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 2015; 373: 317–327.
Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med 2015; 373: 307–316.
Thorsen, 2014, DBCG-IM: improved survival with internal mammary node irradiation: a prospective study on 3,072 breast cancer patients, Radiother Oncol
Poortmans, 2014, Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate, Lancet, 383, 2104, 10.1016/S0140-6736(14)60192-6
Offersen, 2015, ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, Radiother Oncol, 114, 3, 10.1016/j.radonc.2014.11.030
Whelan, 2010, Long-term results of hypofractionated radiation therapy for breast cancer, N Engl J Med, 362, 513, 10.1056/NEJMoa0906260
Bentzen, 2008, The UK Standardisation of Breast Radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, Lancet, 371, 1098, 10.1016/S0140-6736(08)60348-7
Bentzen, 2008, The UK Standardisation of Breast Radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, Lancet Oncol, 9, 331, 10.1016/S1470-2045(08)70077-9
Adams, 2010, Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival, Breast Cancer Res Treat, 124, 723, 10.1007/s10549-010-1181-8
Goodwin, 2009, Post-operative radiotherapy for ductal carcinoma in situ of the breast—a systematic review of the randomized trials, Breast, 18, 143, 10.1016/j.breast.2009.04.003
Morrow, 2015, Current management of lesions associated with an increased risk of breast cancer. Current management of lesions associated with an increased risk of breast cancer, Nat Rev Clin Oncol, 12, 227, 10.1038/nrclinonc.2015.8
Lohrisch, 2006, Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer, J Clin Oncol, 24, 4888, 10.1200/JCO.2005.01.6089
Peto, 2012, Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, Lancet, 379, 432, 10.1016/S0140-6736(11)61625-5
Harbeck, 2002, Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3424), Cancer Res, 62, 4617
Paik, 2004, A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, 351, 2817, 10.1056/NEJMoa041588
Azim, 2013, Utility of prognostic genomic tests in breast cancer practice: the IMPAKT 2012 working group consensus statement, Ann Oncol, 24, 647, 10.1093/annonc/mds645
Dowsett, 2013, Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy, J Clin Oncol, 31, 2783, 10.1200/JCO.2012.46.1558
Dubsky, 2013, The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients, Br J Cancer, 109, 2959, 10.1038/bjc.2013.671
Tolaney, 2015, Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer, N Engl J Med, 372, 134, 10.1056/NEJMoa1406281
Albain, 2009, Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial, Lancet, 374, 2055, 10.1016/S0140-6736(09)61523-3
Colleoni, 2006, Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group trial 13–93, J Clin Oncol, 24, 1332, 10.1200/JCO.2005.03.0783
Early Breast Cancer Trialists' Collaborative Group, 2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016/S0140-6736(05)66544-0
Goss, 2003, A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer, N Engl J Med, 349, 1793, 10.1056/NEJMoa032312
Cuzick, 2007, Use of luteinizing-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials, Lancet, 369, 1711, 10.1016/S0140-6736(07)60778-8
Davidson, 2005, Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188), J Clin Oncol, 23, 5973, 10.1200/JCO.2005.05.551
Swain, 2010, Amenorrhea from breast cancer therapy—not a matter of dose, N Engl J Med, 363, 2268, 10.1056/NEJMc1009616
Pagani, 1998, Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI, Eur J Cancer, 34, 632, 10.1016/S0959-8049(97)10036-3
Francis, 2015, Adjuvant ovarian suppression in premenopausal breast cancer, N Engl J Med, 372, 436, 10.1056/NEJMoa1412379
Gnant, 2009, Endocrine therapy plus zoledronic acid in premenopausal breast cancer, N Engl J Med, 360, 679, 10.1056/NEJMoa0806285
Pagani, 2014, Adjuvant exemestane with ovarian suppression in premenopausal breast cancer, N Engl J Med, 371, 107, 10.1056/NEJMoa1404037
Jonat, 2002, Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association study, J Clin Oncol, 20, 4628, 10.1200/JCO.2002.05.042
Moore, 2015, Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy, N Engl J Med, 372, 923, 10.1056/NEJMoa1413204
Bliss, 2012, Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study, J Clin Oncol, 30, 709, 10.1200/JCO.2010.33.7899
Regan, 2011, Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8.1 years median follow-up, Lancet Oncol, 12, 1101, 10.1016/S1470-2045(11)70270-4
Cuzick, 2010, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial, Lancet Oncol, 11, 1135, 10.1016/S1470-2045(10)70257-6
Goss, 2008, Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen, J Clin Oncol, 26, 1948, 10.1200/JCO.2007.11.6798
Burstein, 2010, American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer, J Clin Oncol, 28, 3784, 10.1200/JCO.2009.26.3756
Dowsett, 2010, Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen, J Clin Oncol, 28, 509, 10.1200/JCO.2009.23.1274
Davies, 2013, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, Lancet, 381, 805, 10.1016/S0140-6736(12)61963-1
Regan MM, Leyland-Jones B, Bouzyk M, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trial. J Natl Cancer Inst 2012; 104: 441–451.
Sideras, 2010, Coprescription of tamoxifen and medications that inhibit CYP2D6, J Clin Oncol, 28, 2768, 10.1200/JCO.2009.23.8931
Berry, 2006, Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer, JAMA, 295, 1658, 10.1001/jama.295.14.1658
Clarke, 2008, Adjuvant chemotherapy in oestrogen receptor-poor breast cancer: patient-level meta-analysis of randomised trials, Lancet, 371, 29, 10.1016/S0140-6736(08)60069-0
Geyer, 2014, A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer, SABCS, S3-02
Di Leo, 2011, HER2 And TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data, Lancet Oncol, 12, 1134, 10.1016/S1470-2045(11)70231-5
Gianni, 2009, Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer, J Clin Oncol, 27, 2474, 10.1200/JCO.2008.19.2567
Shao, 2012, Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials, Breast, 21, 389, 10.1016/j.breast.2012.03.011
Earl, 2014, Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial, Lancet Oncol, 15, 201, 10.1016/S1470-2045(13)70554-0
Jones, 2009, Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735, J Clin Oncol, 27, 1177, 10.1200/JCO.2008.18.4028
Gianni, 2011, Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-?year follow-up of a randomised controlled trial, Lancet Oncol, 12, 236, 10.1016/S1470-2045(11)70033-X
Perez, 2014, Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831, J Clin Oncol, 32, 3744, 10.1200/JCO.2014.55.5730
Slamon, 2011, Adjuvant trastuzumab in HER2-positive breast cancer, N Engl J Med, 365, 1273, 10.1056/NEJMoa0910383
Gonzalez-Angulo, 2009, High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller, J Clin Oncol, 27, 5700, 10.1200/JCO.2009.23.2025
Joensuu, 2009, Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial, J Clin Oncol, 27, 5685, 10.1200/JCO.2008.21.4577
Goldhirsch, 2013, 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial, Lancet, 382, 1021, 10.1016/S0140-6736(13)61094-6
Pivot, 2013, 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial, Lancet Oncol, 14, 741, 10.1016/S1470-2045(13)70225-0
Baselga, 2012, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial, Lancet, 379, 633, 10.1016/S0140-6736(11)61847-3
Guarneri, 2012, Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study, J Clin Oncol, 30, 1989, 10.1200/JCO.2011.39.0823
Gianni, 2012, Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial, Lancet Oncol, 13, 25, 10.1016/S1470-2045(11)70336-9
Piccart-Gebhart, 2014, J Clin Oncol, 32, 5s
Coleman, 2014, Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomized open-label phase 3 trial, Lancet Oncol, 15, 997, 10.1016/S1470-2045(14)70302-X
Coleman, 2013, Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials, SABCS, S4-07
Eidtmann, 2010, Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study, Ann Oncol, 21, 2188, 10.1093/annonc/mdq217
Reid, 2008, Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group, Cancer Treat Rev, 34, S3, 10.1016/j.ctrv.2008.03.007
Muss, 2009, Adjuvant chemotherapy in older women with early-stage breast cancer, N Engl J Med, 360, 2055, 10.1056/NEJMoa0810266
Perrone, 2015, Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial, Ann Oncol, 26, 675, 10.1093/annonc/mdu564
Crivellari, 2013, Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a ‘standard chemotherapy regimen’: the CASA randomized trial, Breast, 22, 130, 10.1016/j.breast.2013.01.015
Staley, 2012, Postoperative tamoxifen for ductal carcinoma in situ, Cochrane Database Syst Rev, 10, CD007847
Rastogi, 2008, Preoperative chemotherapy: updates of?National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27, J Clin Oncol, 26, 778, 10.1200/JCO.2007.15.0235
von Minckwitz, 2014, Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial, Lancet Oncol, 15, 747, 10.1016/S1470-2045(14)70160-3
Rugo, 2013, Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: first efficacy results from the I-SPY 2 TRIAL, SABCS, S5-02
von Minckwitz, 2011, Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials, Breast Cancer Res Treat, 125, 145, 10.1007/s10549-010-1228-x
Cataliotti, 2006, Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative ‘Arimidex’ compared to tamoxifen (PROACT) trial, Cancer, 106, 2095, 10.1002/cncr.21872
Smith, 2005, Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial, J Clin Oncol, 23, 5108, 10.1200/JCO.2005.04.005
Eiermann, 2001, Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double blind multicenter study, Ann Oncol, 12, 1527, 10.1023/A:1013128213451
Eggemann, 2013, Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients, Breast Cancer Res Treat, 137, 465, 10.1007/s10549-012-2355-3
Korde, 2010, Multidisciplinary meeting on male breast cancer: summary and research recommendations, J Clin Oncol, 28, 2114, 10.1200/JCO.2009.25.5729
Sousa, 2013, An update on male breast cancer and future directions for research and treatment, Eur J Pharmacol, 717, 71, 10.1016/j.ejphar.2013.03.037
Cardoso, 2014, Characterization of male breast cancer: first results of the EORTC 10085/TBCRC/BIG/NABCG International Male BC Program, SABCS, S6-05
Allemani, 2013, Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000–2002, Int J Cancer, 132, 2404, 10.1002/ijc.27895
Park, 2012, Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry, Breast, 21, 50, 10.1016/j.breast.2011.07.008
Holmes, 2005, Physical activity and survival after breast cancer diagnosis, JAMA, 293, 2479, 10.1001/jama.293.20.2479
Chlebowski, 2002, Weight loss in breast cancer patient management, J Clin Oncol, 20, 1128, 10.1200/JCO.2002.20.4.1128
Holmberg, 2008, Increased risk of recurrence after hormone replacement therapy in breast cancer survivors, J Natl Cancer Inst, 100, 475, 10.1093/jnci/djn058